Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
Rangering i aksjer
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Aksjekurs
$6.17
Markedsverdi
$3.52B
Endring (1 dag)
-0.05%
Endring (1 år)
-1.86%
Land
CN
Handel Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Kategori
Healthcare
P/E-forhold for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
P/E-forhold per October 2026 TTM: 37.37
Ifølge Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 37.37. Ved slutten av 2024 hadde selskapet en P/E på 10.64.
P/E-forholdshistorikk for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited fra 2001 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 37.37 | 126.89% |
| 2025 | 16.47 | 54.78% |
| 2024 | 10.64 | -59.53% |
| 2023 | 26.29 | 1.26% |
| 2022 | 25.96 | -17.31% |
| 2021 | 31.40 | 54.24% |
| 2020 | 20.36 | 19.50% |
| 2019 | 17.04 | 4.75% |
| 2018 | 16.26 | -32.78% |
| 2017 | 24.19 | -23.66% |
| 2016 | 31.69 | -10.14% |
| 2015 | 35.27 | 10.93% |
| 2014 | 31.79 | 20.92% |
| 2013 | 26.29 | 48.82% |
| 2012 | 17.67 | -37.71% |
| 2011 | 28.36 | -22.02% |
| 2010 | 36.38 | 17.88% |
| 2009 | 30.86 | 65.68% |
| 2008 | 18.63 | -130.45% |
| 2007 | -61.16 | 1,134.91% |
| 2006 | -4.95 | -127.87% |
| 2005 | 17.77 | -39.63% |
| 2004 | 29.44 | 10.44% |
| 2003 | 26.66 | -36.86% |
| 2002 | 42.22 | -45.27% |
| 2001 | 77.13 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 55.58 | 48.72% |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -6.45% |
IN
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.